STAT
Pharmalot
A small drug maker accuses Soon-Shiong of masterminding a ‘catch-and-kill’ scheme
By Ed Silverman @Pharmalot
April 3, 2019
Dr. Patrick Soon-Shiong
Darren McCollester/Getty Images
Twitter
Facebook
LinkedIn
Email
Doximity
Print
In the latest dust-up involving Dr. Patrick Soon-Shiong, a fledgling drug maker alleges the controversial entrepreneur “masterminded” a “catch-and-kill” scheme to rob it of a potentially valuable cancer medicine that might have one day saved the U.S. health care system more than $1 billion.
At issue is a deal that took place four years ago for a chemotherapy that Sorrento Therapeutics was developing to rival Abraxane, a blockbuster breast cancer treatment sold by Celgene (CELG). At the time, Soon-Shiong was the largest Celgene shareholder, after having sold Abraxane to the biotech in 2010 for $2.9 billion.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTED
Log In | Learn More
Twitter
Facebook
LinkedIn
Email
Doximity
Print
Ketamine Depression
Recommended Stories
Scorecard
Biotech
The biotech scorecard for the second quarter: 17 stock-moving events to watch
By Adam Feuerstein
Bacteriophage illustration
Biotech
Can CRISPR improve on nature’s own bacteria-killing phages?
By Eric Boodman
Biotech
In biotech’s biggest hub, companies open their labs to an unlikely inspector: the city’s veterinarian
By Kate Sheridan
Cyclerion
Biotech
Maturing Ironwood is spinning off Cyclerion, its edgy, risk-taking kid brother
By Jonathan Saltzman — Boston Globe
Biotech
It’s only test tubes and mice, but Rubius Therapeutics hails first new data on red blood cell-derived cancer drugs
By Adam Feuerstein
Reporting from the frontiers of health and medicine
STAT
About
Awards for STAT
Contact Us
Meet the STAT Team
Work at STAT
Advertise
Partner with Us
STAT Madness
STAT Wunderkinds
Job Board
Editorial & Events Calendar
Back to Top
Privacy
Comment Policy
Terms
© 2019 STAT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment